Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 23Leukemia, Lymphocytic, Chronic, B-Cell 16Lymphoma, Mantle-Cell 14Lymphoma, Follicular 11Waldenstrom Macroglobulinemia 8Lymphoma 7Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Recurrence 4Lymphoma, Non-Hodgkin 3Neoplasms 1Multiple Myeloma 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, B-Cell 1Leukemia 1Intraocular Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1Cardiovascular Diseases 1

Interventions

Cyclophosphamide 254fludarabine phosphate 165Cytarabine 160Methotrexate 128Busulfan 115Filgrastim 111fludarabine 102Peripheral Blood Stem Cell Transplantation 96Rituximab 94Antilymphocyte Serum 83Etoposide 81Cyclosporine 75Tacrolimus 74Mycophenolic Acid 73Whole-Body Irradiation 72Radiotherapy 70Melphalan 66Vincristine 55Dexamethasone 54Granulocyte Colony-Stimulating Factor 50Methylprednisolone 48Azacitidine 44Alemtuzumab 42Imatinib Mesylate 41Clofarabine 41sargramostim 40Idarubicin 36Daunorubicin 36Cord Blood Stem Cell Transplantation 36Mercaptopurine 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia × zanubrutinib × Clear all
NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡